Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The Inducement grant is used exclusively for the grant of an equity award to an individual who was not previously an employee or non-employee director of the Company (or following a bona fide period of non-employment) as an inducement material to such an individual entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005472/en/
Savara Inc. IR & PR
Anne Erickson (firstname.lastname@example.org)